tut tut
Fine 10% om dagen nå på brukbart volum 
1 Like
»Ingen ved om Bavarian Nordics viser sig at lykkes med, hvad de indledende håber, og ingen ved om de andre vacciner i større studier ikke er bedre end de foregående. Men hvis og kun hvis: Bavarian Nordic lykkes med sit forehavende kan mulighederne for at de har den universelle boostervaccine, som kan blive en form for standard, være gode,« mener Per Hansen.
1 Like
EXPRES2ION BIOTECHNOLOGIES
ExpreS2ion Announces Formation of Oncology Scientific Advisory Board (Cision)
2022-11-03 10:30
Hørsholm, Denmark, November 3, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces the establishment of an Oncology Scientific Advisory Board (OSAB). The six initial members of the ExpreS2ion OSAB bring a depth of knowledge in oncology, breast cancer, clinical trials and therapeutic HER2 vaccines, and will contribute to the development of ExpreS2ion’s proprietary HER2-cVLP breast cancer vaccine, ES2B-C001. The OSAB will serve as advisors, potential contributors to the planned clinical studies and participants in Key Opinion Leader events for the scientific community and investors.
Chief Executive Officer Bent Frandsen comments:
“It is with considerable pride that we announce the establishment of our Oncology Scientific Advisory Board, comprised of six renowned scientists whom I am confident will facilitate the development of ES2B-C001 in a manner that optimizes its potential. As ES2B-C001 gains momentum on its progress towards clinical development, ExpreS2ion is at a critical juncture in which the OSAB will augment the Company’s already deep R&D competencies. On behalf of ExpreS2ion, I welcome our new OSAB members to the ExpreS2ion story and look forward to developing a therapy that will potentially benefit women suffering from HER2-expressing breast cancer worldwide.”
1 Like
Initial trial results are expected in the early part of 2023, which is a slight delay from the original plan due to a delayed recruitment initiation caused by late regulatory challenges and logistics associated with the comparator vaccine.
Tror bava har 0/0 treff på guidingen sin når det gjelder covid vaksinen 
Nano vibber 
Readout kan komme når som helst nå.
Gode data mot flere varianter.
1 stikk holder i lang tid, muligens flere år.
Vaksinen kan lagres i kjøleskap. Ingen behov for å fryses.
Ingen adjuvant. Mindre bivirkninger.
Aksjen har steget 70% på noen måneder nå. Dog falt mye fra toppen.
Posisjonering inc mot phase III readout.
1 Like
I am truly excited to join Bent and his team of highly skilled scientists, who have developed one of the currently most exciting pipelines in the biotech industry with unique vaccine candidates to prevent COVID-19 and treat breast cancer. I am looking forward to create further value out of ExpreS2ion’s vaccine technology platform.”
“This is the first year ExpreS[2]ion will participate in the annual J.P. Morgan Healthcare Conference and the associated Biotech Showcase. We are looking forward to introducing ExpreS[2]ion’s pipeline and platform to a new global audience, obtaining inspiration from the world’s leading healthcare companies, and expanding our network at the world’s largest annual healthcare investment symposium,” says CEO Bent Frandsen.
Another one bites the dust.
Det frister å ta et bet her pga kursfallet, bava ceo uttalte allerede i januar i et intervju om sen rekruttering. Men som alltid reagerer markedet hardere ved en PM.
Når det kommer til expres2ion så er det ikke mye penger igjen i kassa, og nå som utsettelsen er godt over 6mnd på overtid så kan det lugge til med en emisjon før royalties går til expres2ion.
Det eneste som kan dra kursen før studien er fullt innrullert og data avlest, er forhånds bestillinger av vaksinen tenker jeg.
Men med tanke på dagens covid situasjon så er hypen over og det ser ut til at både expres2ion og bava er late 2 the party
12mndr data fra fase2 studien kan kanskje redde det inn om det viser seg at varigheten av beskyttelsen er god 
2 Likes
Bava står til stryk er min mening
2 Likes
Pareto sier de ikke kommer med en oppdatering etter meldingen onsdag. Det har kanskje sammenheng med at de har tatt ned bidraget fra COVID-vaksinen tidligere. Siste fra de er TP 25.
Fornuftig nå å avvente hvordan de løser finansene. Det er vel et stykke frem til andre produktinntekter og ev royalties? Kan de finne på å selge AdaptVac andelen?
PAS: Rights issue of up to SEK 102m to be proposed at 23 March EGM
On 3 March, the company announced a proposed rights issue that would result in initial gross proceeds of between SEK 51m and SEK 102m in mid-April, with scope for additional proceeds of a similar order of magnitude in connection with the exercise of linked warrants. The proceeds will be used to finance the further development of the breast cancer vaccine candidate ES2B-C001, a key value driver expected to be phase I-ready towards year-end, and to invest into the company’s platform technology and pipeline expansion. The proposed measures are consistent with previous communication and decrease ExpreS2ion’s reliance on potential future cash flows from ABNCoV2 (COVID-19, phase III). We rate the shares a Buy as we regard ABNCoV2 and ES2B-C001 as under-rated by the market and note scope for accelerated maturation of the pre-clinical pipeline in the event of a successful rights issue.
Det er vel bare å vente til støvet har lagt seg …
… lugter all time low her.
Ser Discorden mener garantistene betaler 4,9 SEK. Da skal den vel dit i løpet av april?
Da kom resultatet:
2023-04-14 20:32:12 CET
EXPRESSION BIOTECH: TILLFÖRS 55 MLN KR EFTER EMISSION
STOCKHOLM (Nyhetsbyrån Direkt) Vaccinutvecklaren Expression Biotech meddelar att 53,2 procent av företrädesemissionen tecknades. Bolaget tillförs därmed 54,5 miljoner kronor före emissionskostnader.
Det framgår av ett pressmeddelande.
Drygt 47 procent av emissionen tecknades med hjälp av teckningsrätter och 6,2 procent tecknades utan hjälp av sådana. Inga garantiåtaganden utnyttjades.
–
Det som ble meldt tidlig i mars:
2023-03-03 20:36:36 CET
EXPRESSION BIOTECH: OFFENTLIGGÖR FÖRETRÄDESEMISSION, 102 MLN KR
STOCKHOLM (Nyhetsbyrån Direkt) Vaccinutvecklaren Expression Biotech har offentliggjort en företrädesemission med teckningskursen 4:90 kronor per unit, där en unit ger en aktie.
Det framgår av ett pressmeddelande.
Vid fullt utnyttjande kommer bolaget att tillföras omkring 102 miljoner kronor före transaktionskostnader.
Emissionslikviden kommer bland annat att användas till att fortsätta utvecklingen av bröstcancervaccinskandidaten ES2B-C001 samt intern teknologisk utveckling.
Cirka 50 procent av emissionen är garanterad och vid fullt utnyttjande sker en utspädning på omkring 35,7 procent av aktier och röster.
–
De fikk ikke inn maks av meldt beløp (ca halvparten), men så ser det ut som de ikke brukte garantistene, hva kan ligge bak det? Og hvor lenge holder 54 mSEK?
Og PAS update:
On 14 April, the company announced the results of its rights issue. Initial gross proceeds amount to SEK 54.5m, with scope for further inflows in September from the potential exercise of linked warrants. We understand from management that this outcome is likely sufficient to get the breast cancer vaccine ES2B-C001 phase I-ready. We reckon that any clinical work from 2024e would require further external financing, barring a successful launch of the COVID-19 vaccine ABNCoV2, which management has prudently excluded from its forecast. We continue to rate the shares a Buy and set a price target of SEK 14 per share, assuming full dilution from TO8 warrants.
Initial gross proceeds amount to SEK 54.5m, or ca. 53% of the targeted maximum amount. As a result, the number of shares outstanding increases to 48,722,194, from 37,606,796, resulting in nearly 23% dilution for shareholders who did not participate. The potential exercise of warrants from the TO8 series from 7 to 21 September could result in further inflows of a similar order of magnitude based on the same terms as the initial rights issue; we note, however, that the exercise price is linked to the share price in the preceding weeks. The latter is likely to be influenced by ABNCoV2 data (ph III; ph II durability) expected mid-year